Toshifumi Yokota

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 44

Top Topics

Myasthenia Gravis

Muscular Dystrophy

Top Venues

Journal of personalized medicine

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Umme Sabrina Haque, Toshifumi Yokota
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges. Genes 15 (8) (2024)
Saeed Anwar, Toshifumi Yokota
The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments. Biomolecules 14 (3) (2024)
Jamie Leckie, Toshifumi Yokota
Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA. Molecules (Basel, Switzerland) 29 (11) (2024)
Harry Wilton-Clark, Eric Yan, Toshifumi Yokota
Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. Genes 15 (7) (2024)
Saeed Anwar, Toshifumi Yokota
The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments. Biomolecules 14 (3) (2024)
Umme Sabrina Haque, Toshifumi Yokota
Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges. Genes 15 (8) (2024)
Saeed Anwar, Toshifumi Yokota
The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments. Biomolecules 14 (3) (2024)
Jamie Leckie, Toshifumi Yokota
Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA. Molecules (Basel, Switzerland) 29 (11) (2024)
Harry Wilton-Clark, Eric Yan, Toshifumi Yokota
Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. Genes 15 (7) (2024)
Harry Wilton-Clark, Eric Yan, Toshifumi Yokota
Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases. Genes 15 (7) (2024)
Saeed Anwar, Toshifumi Yokota
Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers. Genes 14 (12) (2023)
Saeed Anwar, Farin Mir, Toshifumi Yokota
Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies. Pharmaceutics 15 (4) (2023)
Tejal Aslesh, Ammar Al-Aghbari, Toshifumi Yokota
Assessing the Role of Aquaporin 4 in Skeletal Muscle Function. International journal of molecular sciences 24 (2) (2023)
Saeed Anwar, Farin Mir, Toshifumi Yokota
Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies. Pharmaceutics 15 (4) (2023)
Harry Wilton-Clark, Toshifumi Yokota
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics 15 (3) (2023)
Tejal Aslesh, Ammar Al-Aghbari, Toshifumi Yokota
Assessing the Role of Aquaporin 4 in Skeletal Muscle Function. International journal of molecular sciences 24 (2) (2023)
Saeed Anwar, Toshifumi Yokota
Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers. Genes 14 (12) (2023)
Harry Wilton-Clark, Ammar Al-Aghbari, Jessica Yang, Toshifumi Yokota
Advancing Epidemiology and Genetic Approaches for the Treatment of Spinal and Bulbar Muscular Atrophy: Focus on Prevalence in the Indigenous Population of Western Canada. Genes 14 (8) (2023)
Tejal Aslesh, Ammar Al-Aghbari, Toshifumi Yokota
Assessing the Role of Aquaporin 4 in Skeletal Muscle Function. International journal of molecular sciences 24 (2) (2023)
Saeed Anwar, Farin Mir, Toshifumi Yokota
Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies. Pharmaceutics 15 (4) (2023)
Tejal Aslesh, Ammar Al-Aghbari, Toshifumi Yokota
Assessing the Role of Aquaporin 4 in Skeletal Muscle Function. International journal of molecular sciences 24 (2) (2023)
Harry Wilton-Clark, Toshifumi Yokota
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics 15 (3) (2023)
Saeed Anwar, Toshifumi Yokota
Navigating the Complex Landscape of Fibrodysplasia Ossificans Progressiva: From Current Paradigms to Therapeutic Frontiers. Genes 14 (12) (2023)
Harry Wilton-Clark, Toshifumi Yokota
Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics 15 (3) (2023)
Alex Zhu, Shuntaro Chiba, Yuki Shimizu, Katsuhiko Kunitake, Yasushi Okuno, Yoshitsugu Aoki, Toshifumi Yokota
Ensemble-Learning and Feature Selection Techniques for Enhanced Antisense Oligonucleotide Efficacy Prediction in Exon Skipping. Pharmaceutics 15 (7) (2023)
Umme Sabrina Haque, Toshifumi Yokota
Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells 12 (19) (2023)
Saeed Anwar, Farin Mir, Toshifumi Yokota
Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies. Pharmaceutics 15 (4) (2023)
Satomi Shirakaki, Rohini Roy Roshmi, Toshifumi Yokota
Genetic Approaches for the Treatment of Giant Axonal Neuropathy. Journal of personalized medicine 13 (1) (2022)
Harry Wilton-Clark, Toshifumi Yokota
Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot. Genes 13 (2) (2022)
Satomi Shirakaki, Rohini Roy Roshmi, Toshifumi Yokota
Genetic Approaches for the Treatment of Giant Axonal Neuropathy. Journal of personalized medicine 13 (1) (2022)
Tejal Aslesh, Toshifumi Yokota
Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy. Cells 11 (3) (2022)
Esra J N Erkut, Toshifumi Yokota
CRISPR Therapeutics for Duchenne Muscular Dystrophy. International journal of molecular sciences 23 (3) (2022)
Satomi Shirakaki, Rohini Roy Roshmi, Toshifumi Yokota
Genetic Approaches for the Treatment of Giant Axonal Neuropathy. Journal of personalized medicine 13 (1) (2022)
Satomi Shirakaki, Rohini Roy Roshmi, Toshifumi Yokota
Genetic Approaches for the Treatment of Giant Axonal Neuropathy. Journal of personalized medicine 13 (1) (2022)
Saeed Anwar, Merry He, Kenji Rowel Q Lim, Rika Maruyama, Toshifumi Yokota
A Genotype-Phenotype Correlation Study of Exon Skip-Equivalent In-Frame Deletions and Exon Skip-Amenable Out-of-Frame Deletions across the DMD Gene to Simulate the Effects of Exon-Skipping Therapies: A Meta-Analysis. Journal of personalized medicine 11 (1) (2021)
Rohini Roy Roshmi, Toshifumi Yokota
Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience. Clinical pharmacology : advances and applications 13 (2021)
Kenji Rowel Q Lim, Rika Maruyama, Yusuke Echigoya, Quynh Nguyen, Aiping Zhang, Hunain Khawaja, Sreetama Sen Chandra, Takako Jones, Peter Jones, Yi-Wen Chen, Toshifumi Yokota
Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America 117 (28) (2020)
Adam J Bittel, Sen Chandra Sreetama, Daniel C Bittel, Adam Horn, James S Novak, Toshifumi Yokota, Aiping Zhang, Rika Maruyama, Kenji Rowel Q Lim, Jyoti K Jaiswal, Yi-Wen Chen
Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy. International journal of molecular sciences 21 (15) (2020)
Jaeho Hwang, Toshifumi Yokota
Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies. Expert reviews in molecular medicine 21 (2019)
Yuko Shimizu-Motohashi, Hirofumi Komaki, Norio Motohashi, Shin'ichi Takeda, Toshifumi Yokota, Yoshitsugu Aoki
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches. Journal of personalized medicine 9 (1) (2019)
Yusuke Echigoya, Kenji Rowel Q Lim, Akinori Nakamura, Toshifumi Yokota
Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges. Journal of personalized medicine 8 (4) (2018)
Kenji Rowel Q Lim, Chantal Yoon, Toshifumi Yokota
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy. Journal of personalized medicine 8 (4) (2018)
Tejal Aslesh, Rika Maruyama, Toshifumi Yokota
Skipping Multiple Exons to Treat DMD-Promises and Challenges. Biomedicines 6 (1) (2018)
Quynh Nguyen, Toshifumi Yokota
Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy. Journal of personalized medicine 7 (4) (2017)